Website : www.alterface.com

News : http://www.alterface.com/fr/news

A spin-off company from the université catholique de Louvain (Louvain-la-Neuve, Belgium), after many years of European research in the laboratory of Télécommunication et Télédétection, Alterface has been in business since 2001.

Alterface S.A. offers a range of interactive multimedia systems that are innovative and natural, fun and educational, for museums, houses of science and attraction parks.

Combining innovation and industrial quality, Alterface developed the software engine Salto™, a sturdy tool for the management of interactive systems and designed to operate 24 hours a day, 7 days a week in public places.

Determined to offer an all-inclusive service to its clients, Alterface is versed in all the stages of project development as the company has integrated departments for design, R&D and content integration.  Alterface has a full range of High Definition video editing software as well as dedicated computer equipment for 3D in High Definition. Alterface can meet any sort of eventuality, whether it is technological, content or interactivity.  Alterface has patents on innovative technology for its installations.  A visionary leader, Alterface also invests in a variety of research projects on a European level so that it can supply its clients with increasingly richer and natural interactive solutions.

Alterface is developing new modes of communication and entertainment that will allow users to immerse themselves in information and to react to it intuitively. Alterface is well placed to do this with its extensive know-how in the area of computer vision and signal processing (images and sounds) in real time as well as spectacular content and realist videos.

Key information  (on 30/06/2008)

• Sector: ICT - Entertainment / Edutainment
• Foundation: 18/12/2001
• Business activities: designing and installing communication systems, for education and entertainment using advanced technologies (computers, software, sensor cameras and other means)
• Head Office: Chemin des Etoiles 8, B-1348 Louvain-la-Neuve
• CEO: Benoît Cornet
• Share capital: € 2,345,496
• Turnover: NA
• Employees: 17

Website : www.brucells.com

News : http://www.brucells.com/taxonomy/term/17

BruCells was set up April 2002 in order to proceed with the development of therapeutic cellular vaccines based on patents and know-how developed by the Université Libre de Bruxelles (ULB) and Vrije Universiteit Brussel (VUB). The scientific collaboration was extended in 2003 to the Université Catholique de Louvain (UCL) and the Brussels branch of the Institut Ludwig for cancer research (LICR). The developments are financed in part by the industrial partners and by grants from the government of the Brussels-Capital region.

These vaccines use the unique properties of Dendritic cells (DCs), a small sub-population of white cells in order to activate the sentinels of the immune system (lymphocytes-T). By artificially grafting the dendritic cells with the antigens associated with tumours, it is possible to teach the immune system of the patient to destroy his own cancer cells.

The company is currently developing two types of vaccine, notably:

1. Dendritic cells fused with tumorous cells;
2. Dendritic cells fused ex-vivo with proteins or peptides associated with the antigens of tumours.

Since 2006, the company has been concentrating on therapeutic vaccines based on allogenic cells stemming from cell lines.

The company produces and also markets a limited number of cytokines of a clinical nature used in the preparation of cancer vaccines.

Key information (on 30/06/2008)

• Sector: Life sciences
• Foundation: 30/04/2001
• Business activities:  Research, development and marketing of therapeutic principles based on cell therapy
• Head Office: Rue de Ransbeek 310, B-1120 Bruxelles
• CEO: Gilles Capart
• Share capital: € 4,362,580
• Turnover: NA
• Employees: 5

Website : www.cissoid.com

News : http://www.cissoid.com/blogcategory/latest-news.html

CISSOID is the leader in high temperature semiconductor solutions, delivering standard products and custom solutions for power management, power conversion and signal conditioning in extreme temperature and harsh environments. CISSOID provides high reliability products guaranteed from -55°C to +225°C and commonly used outside that range, from cryogenic lows to upper extremes.

Whether the ambient temperature is low but the power dissipation heats up the chips, or in high temperature environments, CISSOID products enable energy, weight and cost savings in lighter, cooling-free and more compact electronic systems. They are used in mission-critical systems as well as in applications requiring long term reliability. CISSOID supplies leaders in the Oil&Gas, Aeronautics, Industrial and Automotive markets.

Key information  (on 31/12/2008)

• Sector: ICT - Electronics
• Foundation: 31/07/2000
• Business activities: the design of analogue micro-electric circuits based on the SOI (circuits integrated with silicon on insulator) procedure
• Head Office: Rue Emile Francqui 3, B-1435 Mont-Saint-Guibert
• CEO: Tony Denayer
• Share capital: € 3,858,720
• Turnover: NA
• Employees: 11

Website : www.e-xstream.com

News : http://www.e-xstream.com/fr/copy_workshops-and-events/

e-Xstream develops the DIGIMAT software platform and offers its consultancy service for multi-scale modelling of materials and composite structures (PMC, RMC, MMC, etc). e-Xstream helps its clients to:

. Develop composite materials and structures in an efficient and effective way;

. To make the most of the exceptional properties of composite materials (performance/freedom of design ratio);

. To lighten their parts in order to reduce gas emissions and raw material consumption;

. To quickly market innovative high-quality products;

. To minimise the number of prototypes in order to reduce costs and shorten the development cycle.

e-Xstream develops DIGIMAT; the only non-linear multi-scale modelling platform for composite structures and materials that responds to the needs of suppliers of materials and final users to design innovative and optimal materials, while at the same time reducing the time and costs associated with this.

e-Xstream supplies its clients with a complete and optimal modelling solution in response to their specific needs and which integrates their existing production processes; from the development of materials (reinforced plastics, rubber, plastic reinforced with carbon fibres, etc.)  to the manufacturing process (injection moulding) right through to use in the final product (structure calculations).

With more than 70 clients in Europe, the United States and Japan, e-Xstream has added to its expertise in numerical simulation, the inclusion of a large range of materials such as reinforced plastics, rubbers, hard metals, sandwich boards and nanocomposites used in the avionics and automotive industries, consumer goods and industrial equipment.

Key information (on 31/12/2008)

• Sector: ICT - Software
• Foundation: 20/05/2003
• Business activities: development, implementation, use, distribution and marketing of numerical simulation software packages
• Head Office: Rue du Bosquet 7, B-1348 Louvain-la-Neuve
• CEO: Roger Assaker
• Share capital: € 300,000
• Turnover: € 676,980
• Employees: 6

Website : www.femagsoft.com

News : http://www.femagsoft.com/a_aboutus_4a/about_conf.htm

FEMAGSoft develops markets and provides back-up for software simulation products, aimed at supplying users with the specialised digital tools and at helping them to design and optimise their processes thanks to computer modelling.

FEMAGSoft particularly develops a software simulation package devoted to crystal growth. The semi-conductor crystals are principally used for the manufacture of microchips, electronics in the wider sense, photovoltaic energy, optoelectronics and the communication industries. The flagship product of FEMAGSoft, FEMAG-CZ, is a high-tech software package for the simulation of the Czochralski growing technique, used by the principal producers of crystal semi-conductors in the world, and compatible with standard software packages for pre and post-analysis treatment.

The FEMAGSoft software product licences include maintenance, user support and personalised training. The technical support helps clients to improve their skills with the simulation software and to solve technical problems linked to specific demands.

Key information (on 31/12/2008)

• Sector: ICT - Software
• Foundation: 24/06/2003
• Business activities: Digital modelling of material shaping procedures and in particular various techniques for growth of monocrystals
• Head Office: Rue André Dumont 7, B-1435 Mont-Saint-Guibert
• CEO: Vincent Regnier
• Share capital: € 354,000
• Turnover: € 477,236
• Employees: 7

Website : www.greenwatt.be

GreenWatt is a company specialising in the design, integration and setting up of biomethanisation installations in two steps, associated with a cogeneration unit.

Biomethanisation – cogeneration is both a renewable energy form and a solution to waste recycling.

Why Biomethanisation cogeneration? Because it provides:

- A modern « green » citizen image

- A solution to profitable waste treatment which is both sustainable and harmless

- Production of quality fertiliser

- Production of renewable electrical and thermal energy with a return on investment in 3 to 7 years

Key information (on 31/12/2008)

• Sector: Green energy
• Foundation: 26/05/2004
• Business activities: promotion, feasibility study, design basis, marketing, construction (placement) and maintenance of renewable energy installations and related material such as wind turbines, solar panels and biomethanisation.
• Head Office: Rue de Libersart 1A, B-1457 Walhain
• CEO: Philippe Mengal
• Share capital: € 850,100
• Turnover: € 477,236
• Employees: 2

Website : www.iba-worldwide.com

News : http://corporate.iba-worldwide.com/news-and-press

Protecting, enhancing and saving lives: IBA develops and markets top of the range technologies, pharmaceutical products and made to measure solutions in the domain of healthcare, with emphasis on cancer diagnosis and therapy. Relying on its scientific expertise, IBA is also active in the area of industrial sterilisation and ionisation.

Key information (on 31/12/2008)

• Sector: Life sciences
• Foundation: 28/03/1986
• Business activities: exploitation of particle accelerator technology in the domain of sterilisation, medical imaging and cancer therapy
• Head Office: Chemin du Cyclotron 3, B-1348 Louvain-la-Neuve
• CEO: Pierre Mottet
• Share capital: € 37,285,426
• Turnover: € 332,607,000 (Consolidated)
• Employees: 2067 (Consolidated)

Website : www.ibt-bebig.eu

News : http://www.ibt-bebig.eu/en/sidenavigation/press/press_releases.html

IBt Bebig is an international medical equipment company whose activities are concentrated on the growing and technologically evolving sector of cancer treatment by radiotherapy.

The aim of IBt Bebig is to develop and manufacture top of the range products for the well-being of patients. Its products are designed not only with a view to maintaining proven clinical efficiency, but also to reduce side effects for the patients and optimal radioprotection for the treating doctors. The low-output radioactive sources for the treatment of tumours by brachtherapy places IBt Bebig among the leaders in the European market.

Radio isotope therapy, also called brachytherapy, is a form of radiotherapy. This procedure makes it possible to introduce the source of radiation around or directly into the tumour (“brachy” comes from the Greek word meaning “short”) in contrast with (“tele” coming from the Greek word for “long”) where the body receives radiation from an external source. The direct distribution of rays in the affected tissues as well as protection of the surrounding healthy tissues are the principal advantages of radio isotope therapy.

One of the forms of radio isotope therapy for prostate cancer is the implanting of radioactive sources, the seeds or granules of iodine in the prostate tissues: these radioactive grains which are only a few millimetres long, are implanted with the help of a needle through the perineum and controlled by ultrasound. The operation generally takes place without hospitalisation, that is to say that the patient can leave the clinic the same day.

Key information (on 31/12/2008)

• Sector: Life sciences
• Foundation: 15/02/1996
• Business activities: the treatment of cancer by brachytherapy (delivering implants with radioisotopes directly into cancer cells)
• Head Office: Zone Industrielle, B-7180 Seneffe
• CEO: François Blondel
• Share capital: € 10,879,027
• Turnover: € 17,240,000 (Consolidated)
• Employees: 148 (Consolidated)

Website : www.intopix.com

News : http://www.intopix.com/contents/index/index/id/15/lang/

Founded in 2005, intoPIX is an independent company of active image technology in the domains of image treatment, cryptography and micro-electronics. IntoPIX offers solutions for the compression and encryption of JPEG 2000 images for the audiovisual market. Its implementation in the most recent generation of FPGA and ASIC chips enables it to supply ultra-flexible economical tools of the highest quality for processing high definition full motion video images in real time. IntoPIX’s range of products includes JPEG 2000 encoders and decoders, video and network interfaces, multimedia and encryption solutions, etc.

Leaders in their field, the employees of intoPIX have made a significant contribution to the JPEG 2000 standardisation committees, physical security and digital cinema since 2001. Since 2005 intoPIX has become the benchmark provider of JPEG 2000 tools for digital cinema and also offers solutions for other audiovisual sectors such as digital acquisition, post-production, distribution and archiving.

Key information (on 30/06/2008)

• Sector: ICT - Electronics
• Foundation: 30/03/2006
• Business activities: research, development and industrialisation of applications and equipment and marketing in informatics and electronics
• Head Office: Place de l'Université 16, B-1348 Louvain-la-Neuve
• CEO: Jean-François Nivart
• Share capital: € 1,375,500
• Turnover: € 547,901
• Employees: 6

Website : www.it4ip.be

News : http://www.it4ip.be/fr_FR/news.html

IT4IP produces and supplies Hi-Tec polymeric membranes. IT4IP develops, produces and supplies unique polymeric membranes based on patented “track etching” technologies. IT4IP aims to become a company specialising in the supply of “track-etched” products in high value added markets in areas as diverse as health, energy and electronics – and to be recognised as the benchmark supplier of these solutions.

Track-etching technology is based on the irradiation of a polymer layer or film with energetic heavy ions leading to the formation of latent linear tracks characterised by damaged tracks in the polymer; these tracks are then revealed into pores using a well-chosen chemical. This track-etching technology is used to manufacture porous polymer membranes characterised by a smooth flat surface and a sharp cut-off.

Key information (on 30/06/2008)

• Sector: Materials
• Foundation: 18/01/2006
• Business activities: development, manufacture and marketing of objects made by an irradiation technique with energetic particles, followed in some cases by revealing the tracks left behind
• Head Office: Rue Jules Bordet 1, B-7180 Seneffe
• CEO: Henri Hanot
• Share capital: € 124,000
• Turnover: NA
• Employees: 2